|
KR101007925B1
|
|
Lipidic nano particles for oral administration and process for preparing the same
|
|
KR20100034721A
|
|
A pharmaceutical composition for preventing or treating nsaid-induced enteropathy comprising zinc acexamate
|
|
KR20100096721A
|
|
Aqueous pharmaceutical composition for parenteral administration
|
|
KR20090052750A
|
|
Valsartan di-potassium salt hydrate and preparation method thereof
|
|
KR100749219B1
|
|
Novel rosiglitazone oxalate salt, preparation method thereof and pharmaceutical composition comprising it
|
|
KR20060102985A
|
|
Preparation method of 2,n-dimethyl-n-(3,3-diphenylpropyl)-1-amino-2-propanol
|
|
KR20060100117A
|
|
PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING alpha;-LIPOIC ACID WITH IMPROVED STABILITY
|
|
KR20060087202A
|
|
Pharmaceutical composition comprising ace inhibitor having superior stability
|
|
KR20050032781A
|
|
A new process for the preparation of lercanidipine hydrochloride
|
|
KR20050013348A
|
|
A new process for the preparation of lercanidipine hydrochloride
|
|
KR20030010445A
|
|
Process for the preparation of L-cystein derivatives
|
|
KR20020038469A
|
|
A process for the preparation of quinolinone derivatives
|
|
KR20020038466A
|
|
A process for the preparation of carbostyryl derivatives
|
|
KR20010049708A
|
|
Novel water soluble polymer-cyclosporine conjugated compounds and process for preparing the same
|
|
KR100244164B1
|
|
Water soluble polymer takurolimus conjugate compounds and its manufacturing process
|
|
KR0131726B1
|
|
Process for preparing sustained released tablet
|
|
KR950013576B1
|
|
Pyranoindoles acetic aluminium compound and process for preparing the same
|
